Stan Miele, President of Sucampo Pharma Americas
Sucampo's lead drug, Amitza, was approved by the FDA for chronic idiopathic constipation in 2006 and irritable bowel syndrome and constipation in 2008. It has been prescribed to 6 million patients. Still the company flies under the radar for many analysts. This may be a breakout year for the Bethesda, MD, company, which has gotten approvals in Japan and the U.K. and is looking for a new indication in the U.S. While 2013 may be a challenge for the industry in general, Sucampo Pharma Americas President Stan Miele says, "All organizations are looking for novel ways to market, but in the end, if you have a product with a novel mechanism and are serving patients with unmet medical needs, there is always a place for a product to be successful."
